CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
- Oil prices settle at pre-Iran war levels as crude output grows
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Broadcom secures role as key Apple supplier with chip deal through 2031
Moderna (MRNA) a catalyst driven idea at Morgan Stanley
January 6, 2023 12:17 PM ESTMorgan Stanley analyst Matthew Harrison labeled Moderna (NASDAQ: MRNA) a Catalyst Driven Idea in a note Friday, maintaining an Equal-Weight rating and $209 price target on the stock.
The analyst told investors the firm expects Moderna's first interim analysis from its Ph3 RSV vaccine study in the near term.
"We believe efficacy and... More
Morgan Stanley Calls Moderna (MRNA) a Catalyst Driven Idea
January 5, 2023 4:09 PM ESTMorgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $209.00 price target on Moderna (NASDAQ: MRNA).
The analyst comments "We expect the first interim analysis from Moderna's Ph3 RSV vaccine study in the near-term. We believe efficacy and safety in-between... More
